Cardiovascular Complications in Patients With COVID-19
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 198
- Locations
- 8
- Primary Endpoint
- Determine the incidence of cardiomyopathies and venous thromboembolism
Study Overview
Brief Summary
Patients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be elevated in a high proportion of patients (one fifth of all patients and 50% of non-survivors) suggesting the possibility of cardiomyopathies. High levels of DDimers (81% of non survivors) and fibrin degradation products are also associated with increased risk of mortality suggesting also the possibility of venous thromboembolism. Therefore, screening for cardiomyopathies and venous thromboembolism could represent an important challenge for patients with COVID-19 management.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •All consecutive patients with COVID-19 infection admitted to the ICU or hospitalized because of severe form (eg: hypoxia, orthopnea, pneumonitis, kidney insufficiency) will be included
Exclusion Criteria
- •Patients under 18 years
Outcomes
Primary Outcomes
Determine the incidence of cardiomyopathies and venous thromboembolism
Time Frame: 28 days
Incidence of cardiomyopathies and/or venous thromboembolism at day 28
Secondary Outcomes
- Mortality(28 days)
- Duration of mechanical ventilation(hospitalisation duration)
- Shock(hospitalisation duration)
- Renal replacement therapy(hospitalisation duration)
- length of stay(hospitalisation duration)
- Mechanical ventilation(hospitalisation duration)